Common Contracts
2 similar Indenture contracts by Cenveo, Inc, Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. (Company) The Bank of New York Mellon Trust Company, N.A. (Trustee) 4.50% Convertible Senior Notes due 2018 INDENTURE Dated as of September 18, 2013Indenture • September 18th, 2013 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
INDENTURE, dated as of September 18, 2013, between Protalix BioTherapeutics, Inc., a Florida corporation, as issuer (the “Company”), and The Bank of New York Mellon Trust Company, N.A., as trustee, conversion agent, registrar and paying agent (in such capacities, the “Trustee”, “Conversion Agent”, “Registrar” and “Paying Agent”, respectively).
CENVEO CORPORATION, as Issuer, CENVEO, INC. AND CERTAIN SUBSIDIARIES OF CENVEO CORPORATION, as Guarantors AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 28, 2012 7.00% Exchangeable Senior Notes due 2017Indenture • March 30th, 2012 • Cenveo, Inc • Commercial printing • New York
INDENTURE dated as of March 28, 2012 between Cenveo Corporation, a Delaware corporation, as issuer (the “Company”), Cenveo, Inc., a Colorado corporation (“Parent”), and the Guarantors (as defined herein) listed on Schedule A hereto and U.S. Bank National Association, a national banking association, as trustee (the “Trustee”).
